- Nano-Cybernetic Biotrek
Dr. Ehsan Gharib is an accomplished and innovative scientist specializing in cancer biology. He currently serves as a Postdoctoral Associate/Senior Scientist at the prestigious Massachusetts Institute of Technology (MIT), where he continues his vital work in developing next-generation cancer diagnostics and therapies.
Dr. Gharib's research is centred on the intricate ways cancer cells alter their genetic activity and metabolic functions. He combines deep expertise in molecular biology with advanced proficiency in bioinformatics and computational biology, allowing him to decode the complex data of cancer genomics and uncover new pathways for treatment. His work has led to a deeper understanding of challenging diseases, most notably Colorectal Cancer (CRC) and Chronic Lymphocytic Leukemia (CLL).
Ehsan earned his Ph.D. in Cellular and Molecular Biology from the University of Tehran. His career has been marked by a series of appointments at distinguished research institutions, including the University of Kentucky and the Université de Moncton (Canada), before his current role at MIT.
Dr. Gharib's work is distinguished by its direct clinical applicability and focus on translating complex biological data into actionable scientific insights. He has pioneered the development of novel, non-invasive biomarker panels that can detect cancer from simple blood or stool samples. These "liquid biopsies" represent a major step forward in early cancer detection, offering a more accessible alternative to traditional methods and improving the potential for early, life-saving intervention.
Key Scientific Contributions
- Pioneering Non-Invasive Diagnostics: Dr. Gharib has developed and validated multiple genetic biomarker panels that can accurately diagnose Colorectal Cancer, predict its recurrence, and distinguish cancers that have spread to the lymph nodes.
- Uncovering Treatment Resistance Mechanisms: In CLL, his research revealed a novel mechanism of chemotherapy resistance, where cancer cells absorb energy-producing mitochondria from platelets to survive treatment, offering new targets to make therapies more effective.
- Developing Novel Therapeutic Strategies: He has identified key molecular targets that can be used to induce cell death in colon cancer cells, paving the way for new therapeutic strategies that exploit the metabolic vulnerabilities of tumors.
- Advanced Bioinformatics and Data Analysis: Dr. Gharib is highly skilled in performing in-depth computational analysis of complex genetic sequencing data, confirming the importance of the molecular targets and pathways he identifies.
At MIT, Dr. Gharib continues to push the boundaries of cancer research, leveraging advanced computational biology and multi-omics techniques to tackle some of the most difficult challenges in oncology, including brain tumors. His work remains dedicated to translating fundamental scientific discoveries into tangible solutions that improve patient outcomes and contribute to the global fight against cancer.